Gossamer Bio, Inc. (FRA:4GB)

Market Cap	662.54M
Revenue (ttm)	37.54M
Net Income (ttm)	-133.10M
Shares Out	n/a
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	91
Open	2.796
Previous Close	2.550
Day's Range	2.786 - 3.010
52-Week Range	0.611 - 3.032
Beta	n/a
RSI	64.43
Earnings Date	Mar 9, 2026

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The compa...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 145
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4GB

Financial Performance

Financial numbers in USD